Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

AIM: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments. MATERIAL OF STUDY: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery. RESULTS: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients. CONCLUSIONS: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalAnnali Italiani di Chirurgia
Volume88
Issue number3
Publication statusPublished - May 1 2017

Fingerprint

Lymphoscintigraphy
Therapeutics
cyhalothrin
Breast Neoplasms

Keywords

  • Breast Cancer
  • Lymphoscintigraphy
  • Neo-Adjuvant Treatment
  • Sentinel lymphnode biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

@article{e0cedf32b41b47f0b19c2f5e72914d9f,
title = "Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy",
abstract = "AIM: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments. MATERIAL OF STUDY: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery. RESULTS: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9{\%} (95{\%} CI, 94.8-98.1{\%}). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients. CONCLUSIONS: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.",
keywords = "Breast Cancer, Lymphoscintigraphy, Neo-Adjuvant Treatment, Sentinel lymphnode biopsy",
author = "Giovanni Corso and Grana, {Chiara Maria} and Laura Gilardi and Baio, {Silvia Melania} and {De Lorenzo}, Daniela and Patrick Maisonneuve and Nicole Rotmensz and Bettina Ballardini and Germana Lissidini and Silvia Ratini and Bassi, {Fabio D.} and Paolo Veronesi and Viviana Galimberti",
year = "2017",
month = "5",
day = "1",
language = "English",
volume = "88",
pages = "201--205",
journal = "Annali Italiani di Chirurgia",
issn = "0003-469X",
publisher = "Edizioni Luigi Pozzi S.r.l.",
number = "3",

}

TY - JOUR

T1 - Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy

AU - Corso, Giovanni

AU - Grana, Chiara Maria

AU - Gilardi, Laura

AU - Baio, Silvia Melania

AU - De Lorenzo, Daniela

AU - Maisonneuve, Patrick

AU - Rotmensz, Nicole

AU - Ballardini, Bettina

AU - Lissidini, Germana

AU - Ratini, Silvia

AU - Bassi, Fabio D.

AU - Veronesi, Paolo

AU - Galimberti, Viviana

PY - 2017/5/1

Y1 - 2017/5/1

N2 - AIM: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments. MATERIAL OF STUDY: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery. RESULTS: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients. CONCLUSIONS: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.

AB - AIM: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments. MATERIAL OF STUDY: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery. RESULTS: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients. CONCLUSIONS: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.

KW - Breast Cancer

KW - Lymphoscintigraphy

KW - Neo-Adjuvant Treatment

KW - Sentinel lymphnode biopsy

UR - http://www.scopus.com/inward/record.url?scp=85024366938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024366938&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85024366938

VL - 88

SP - 201

EP - 205

JO - Annali Italiani di Chirurgia

JF - Annali Italiani di Chirurgia

SN - 0003-469X

IS - 3

ER -